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ABSTRACT
Bile salts, such as cholate, glycocholate, taurocholate, and
glycochenodeoxycholate, are taken up from the portal blood
into hepatocytes via transporters, such as the Na+-taurocholate–
cotransporting polypeptide (NTCP) and organic anion–transporting
polypeptides (OATPs). These bile salts are later secreted into bile
across the canalicular membrane, which is facilitated by the bile
salt export pump (BSEP). Apart from bile salt transport, some of
these proteins (e.g., OATPs) are also key transporters for drug
uptake into hepatocytes. In vivo studies of transporter function
in patients by using tracer compounds have emerged as an
important diagnostic tool to complement classic liver parameter
measurements by determining dynamic liver function both for
diagnosis and monitoring progression or improvement of liver
diseases. Such approaches include use of radioactively labeled
bile salts (e.g., for positron emission tomography) and fluores-
cent bile salt derivatives or dyes (e.g., indocyanine green). To
expand the list of liver function markers, we synthesized
fluorescent derivatives of cholic and chenodeoxycholic acid by
conjugating small organic dyes to the bile acid side chain. These
novel fluorescent probes were able to block substrate transport
in a concentration-dependent manner of NTCP, OATP1B1,
OATP1B3, OATP2B1, BSEP, and intestinal apical sodium-
dependent bile salt transporter (ASBT). Whereas the fluorescent
bile acid derivatives themselves were transported across the
membrane by OATP1B1, OATP1B3, and OATP2B1, they were
not transport substrates for NTCP, ASBT, BSEP, and multidrug
resistance-related protein 2. Accordingly, these novel fluores-
cent bile acid probes can potentially be used as imaging agents
to monitor the function of OATPs.
SIGNIFICANCE STATEMENT
Synthetic modification of common bile acids by attachment of
small organic fluorescent dyes to the bile acid side chain
resulted in bright, fluorescent probes that interact with hepatic
and intestinal organic anion [organic anion–transporting poly-
peptide (OATP) 1B1, OATP1B3, OATP2B1], bile salt uptake
(Na+-taurocholate–cotransporting polypeptide, apical sodium-
dependent bile salt transporter), and bile salt efflux (bile salt
export pump, multidrug resistance-related protein 2) transport-
ers. Although the fluorescent bile salt derivatives are taken up
into cells via the OATPs, the efflux transporters do not transport
any of them but one.
Introduction
Bile formation is one of several important liver functions
(Stieger, 2011). The liver is also a second barrier for preventing
the entry of harmful substances into the body via the oral route
because of its role in detoxification (Corsini and Bortolini, 2013;
Selvapatt et al., 2014). Consequently, the liver is constantly at
risk of insults by xenobiotics, which may lead to liver injury in
susceptible patients (Corsini and Bortolini, 2013).
The major constituents of bile are bile salts (BSs), which are
organic anions like conjugates of bilirubin and lipids (Esteller,
2008). BSs are absorbed from the portal blood into hepatocytes
fromwhich they are secreted across the canalicularmembrane
into bile draining into the small intestine. In the intestine, BSs
are almost quantitatively absorbed and transported back into
the liver by the portal vein, where their journey starts again.
The transport systems involved in hepatocellular handling of
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ABBREVIATIONS: abs, absorption; Acen, acetyl ethylenediamine; ASBT, apical sodium-dependent bile salt transporter; BA, bile acid; br,
broad peak; BS, bile salt; BSEP, bile salt export pump; CDCen, (2-aminoethyl)chenodeoxycholic amide; Cen, (2-aminoethyl)cholic amide; d,
doublet; DCM, dichloromethane; DMF, N,N-dimethylformamide; DNS, Dansyl, 5-(dimethylamino)naphthalene-1-sulfonamide; em, emission; EtOAc,
ethyl acetate; ex, excitation; eq., equivalent; FCS, fetal calf serum; Fluo, fluorescence; HRMS, high-resolution mass spectra; LC, liquid
chromatography; m, multipletMeOH methanol m/z mass-to-charge ratio; MRP, multidrug resistance-related protein; MS, mass spectrometry; NBD,
4-nitrobenzo[c][1,2,5]oxadiazole; NTCP, Na+-taurocholate–cotransporting polypeptide; OATP, organic anion–transporting polypeptide; OST,
organic solute transporter; PB, Pacific Blue, 6,8-difluoro-7-hydroxy-2-oxo-2H-chromene-3-carboxamide; q, quartet; s, singlet; t, triplet; TLC, thin-
layer chromatography; WT, wild type.
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bile acids (BAs) and BSs are known (Stieger, 2011; Pollheimer
et al., 2014) and include for the uptake from the blood
plasma the Na+-taurocholate–cotransporting polypeptide
(NTCP) and the organic anion–transporting polypeptides
(OATPs) OATP1B1, OATP1B3, and OATP2B1. Efflux of BS
from hepatocytes into bile is mediated by the BS export pump
(BSEP). In the intestine, BSs are reclaimed by the apical
sodium-dependent BS transporter (ASBT) in the apical mem-
brane of enterocytes in the distal ileum. Export from enter-
ocytes is accomplished through the basolateral membrane by
the organic solute transporter (OST) a/OSTb (Dawson and
Karpen, 2015). In hepatocytes, MRP3, MRP4, and OSTa/OSTb
are expressed at the basolateral membrane and may act as
salvage transporters for BS in cholestatic conditions (Halilbasic
et al., 2013).
BS export by BSEP constitutes the rate-limiting step of
hepatocellular BS flux. Inherited or acquired impairment of
BSEP function may lead to liver disease (Aithal et al., 2011;
Bull and Thompson, 2018). The substrate specificity of BSEP
is restricted with very few exceptions to BS (Stieger, 2011).
Similarly, the main substrates for NTCP and ASBT are BSs
(Anwer and Stieger, 2014). In addition to contributing to BA
uptake into hepatocytes, OATPs have a broad substrate spec-
ificity and are key transporters for drug uptake (Hagenbuch
and Stieger, 2013).
Measurements of so-called liver parameters are an im-
portant part of diagnosing liver disease. These parameters
often only allow indirect conclusions on liver function. For
example, serum-bilirubin levels give indirect information
on the uptake, metabolic, and excretory/secretory functions
of the liver (Hoekstra et al., 2013). To obtain more direct
functional (or dynamic) information on the liver, in vivo
determination of hepatocellular transporter function has
become an active area of translational research (Stieger
et al., 2012). Recent data show, for instance, that in vivo
determination of liver function by monitoring hepatobiliary
transport of 99mTc-mebrofenin with scintigraphy improves the
outcome of risk assessment for patients needing major liver
resection (Cieslak et al., 2016).
It was recognized that BSs are elevated in plasma in
patients with liver disease (Frosch andWagener, 1967), and
it was later demonstrated that in such patients the clear-
ance of glycocholate is reduced (LaRusso et al., 1975) and
that the clearances of taurocholate and indocyanine green
correlate well (Paumgartner et al., 1979). However, because
of the endogenous BS pool, clearance measurements require
radioactive BS (LaRusso et al., 1975). BS transport in vivo is
currently explored by positron emission tomography, wherein
hepatic transport of a BA derivative can be monitored in
healthy individuals and patients (Cieslak et al., 2016; Kjærgaard
et al., 2021). Such techniques expose patients to internal
radiation and require complex methodologies. An alternate
method is using fluorescence measurements. Spectropho-
tometric determination of indocyanine green clearance is
routinely used to assess liver function (Stieger et al., 2012)
and can also be performed transcutaneously, allowing contin-
uous monitoring of liver function (Sakka, 2018). A pilot study
demonstrated that the plasma clearance of the fluorescent
BS cholyl-lysyl-fluorescein is reduced in patients with liver
cirrhosis compared with healthy controls (Milkiewicz et al.,
2000). However, this BS derivative is neither a substrate of
NTCP nor BSEP (de Waart et al., 2010). Other fluorescein-BS
conjugates like CGamF (Holzinger et al., 1997, 1998) and,
more recently, 18F-labeled BS derivatives (Testa et al., 2017)
have been studied as potential tracers of hepatic transporters
in rat.
In this work, we aimed to test novel fluorescent BAs as
potential liver function indicators. We synthesized novel
fluorescent BA conjugates by modifying the side chain and
tested their interaction with BS transporters using in vitro
test systems. Although the new fluorescent BS conjugates
inhibited all tested transporters except MRP2, these con-
jugates were substrates to OATPs only, albeit to different
extents.
Materials and Methods
Materials Transporter Biology
Radiolabeled [6,7-3H(N)]-estradiol 17b-D-glucuronide, [6,7-3H(N)]-
estrone sulfate, [3H(G)]-taurocholic acid, and scintillation cocktail
Ultima Gold were obtained from PerkinElmer (Schwerzenbach,
Switzerland). [6,7-3H(N)]-estradiol 17b-D-glucuronide and taurocholic
acid sodium salt were from Sigma-Aldrich (St. Louis, MO). Cell Culture
Material: CHO-Flp-In cells and LipofectAMINE 2000 were from Invi-
trogen (Carlsbad, CA). The baculovirus-expressing MRP2 (de Waart
et al., 2010) was the generous gift of Drs. Paulusma and Oude Elferinik,
Academic Medical Center, Amsterdam (The Netherlands).
Transporter Expression Systems
CHO cells stably expressing OATP1B1, OATP1B3, or OATP2B1
were characterized by Treiber et al. (2007) and Gui et al. (2008). The
cells were maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% (v/v) fetal calf serum (FCS): 50 mg/ml L-proline, 100
U/100 mg per ml penicillin/streptomycin, and 500 mg/ml geneticin
sulfate for transfected cells.
The generation of CHO Flp-In cells stably expressing NTCP was
reported by deWaart et al. (2010). The CHO cell line stably expressing
ASBTwas established as follows: CHOFlp-In cells were cotransfected
with pcDNATM5/FRT-hASBT (Zhao et al., 2015) and pOG44 (ratio
1:9) using the LipofectAMINE 2000 method according to the manu-
facturer’s protocol. Cells were selected in medium supplemented with
500 mg/ml hygromycin B, and single clones were obtained by the use
of cloning cylinders. The clones were assessed by determination of
mRNA expression levels and taurocholate transport activity. CHO
Flp-In cells were cultured in HAM-F12 medium enriched with 10% (v/v)
FCS, 1 mM L-glutamine, 100 U/100 mg per ml penicillin/streptomycin,
100 mg/ml Zeocin (control cells), or 500 mg/ml hygromycin B (trans-
fected cells).
The efflux transporter BSEP (Noé et al., 2002) and MRP2 (de
Waart et al., 2006) were expressed with the baculovirus system
in Sf21 cells, and membrane vesicles were isolated as described
(Gerloff et al., 1998). Sf21 cells were grown Grace’s insect medium
containing 10% (v/v) heat-inactivated FCS and penicillin/streptomycin
at 100 U/100 mg per ml.
Transport Experiments
Cell culture and transport experiments with radioactively labeled
substrates were performed as detailed by Wlcek et al. (2013). Prior to
transport experiments, the cells were cultured for 24 hours in the
respective medium containing 5 mM sodium butyrate to increase
protein expression of the transporters (Palermo et al., 1991). The
following substrate concentrations were used for transport experi-
ments with radioactively labeled substrates: 1 mM taurocholate for
ASBT, 5 mM taurocholate for NTCP, 1 mM estrone-3-sulfate for
OATP1B1 and OATP2B1, 5 mM taurocholate for OATP1B3, 10 mM
estradiol 17b-D-glucuronide for MRP2, and 2 mM taurocholate for
Canalicular Transporters Studied with Fluorescent Bile Acids 347
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BSEP. For the kinetic characterization of the established ASBT cell
line, initial uptake rates were first determined (unpublished data).
To test fluorescent compounds as substrates, they were in all experi-
ments used at a concentration of 5 mM. In case of fluorescently
labeled bile salts, the cells were solubilized after the transport
experiment for at least 30 minutes with 1 ml of 1% (w/v) Triton X-
100, and fluorescence was determined in a PerkinElmer LS-55
fluorescence spectrometer.
Transport experiments with vesicles isolated from Sf21 cells
were described by Wlcek et al. (2013). In case of radioactive
substrates, the filters were dissolved in Filter Count liquid
scintillation cocktail from PerkinElmer. In case of experiments
with fluorescent substrates, after the uptake the filters were
incubated in 1 ml of 1% (w/v) Triton X-100 in an Eppendorf tube
for 30 minutes and subsequently centrifuged for 40 minutes in
an Eppendorf FA-45-30-11 rotor at 20,000g. The supernatant was
used for fluorescence determination in a Perkin Elmer LS-55
fluorescence spectrometer.
Analytical Methods
The following settings were used for fluorescence measurements:
for Dansyl (DNS) derivatives, excitation (ex) 335 nm (slit 20 nm) and
emission (em) 520 nm (slit 20 nm); for 4-nitrobenzo[c][1,2,5]oxadiazole
(NBD) derivatives, ex 478 nm (slit 20 nm) and em 545 nm (slit 20 nm);
and for Pacific Blue (PB) derivatives, ex 410 nm (slit 5 nm) and em
451 nm (slit 5 nm). Standard curves were prepared with the
fluorescent substrates in 1% (w/v) Triton X-100. A total membrane
fraction of WT and ASBT-expressing cells was isolated as described
by Huber et al. (2007) and used for Western blotting (Mahdi et al.,
2016). Protein was quantified with the bicinchoninic acid method
(Smith et al., 1985) using the BCA protein assay kit from Interchim
(Montluçon, France).
Chemistry General Remarks
Reagents and solvents were purchased from commercial sources
and were used without further purification or drying. Automated
column chromatography was performed on a TeledyneISCO Combi-
Flash Rf + machine on RediSepRf prepacked columns. Progress of
chemical reactions was monitored on Alugram Xtra Sil G/UV254 TLC
plates with detection of the compounds by UV-visible absorption at
254 nm and 366 nm. Compounds were analyzed by UPLC-MS, and
their purity was assessed by analytical reversed-phase ultra perfor-
mance liquid chromatography (RP-UPLC). RP-UPLC spectra were
obtained from a Dionex Ultimate 3000 RSLC System and a Dionex
Acclaim RSLC 120 column. The following elution method was used: A
gradient from 100% A (milliQ deionized water with 0.05% trifluoro-
acetic acid) to 100% D (high-pressure liquid chromatography–grade
acetonitrile/milliQ deionizedwater 9:1 with 0.05% trifluoroacetic acid)
was applied for 4.5minutes, and this was followed by 100%Dwashing.
Low-resolution mass spectra were acquired on a Thermo Scientific
LCQ Fleet by electron spray ionization in the positive mode. NMR
spectrawere recorded on aBRUKERAdvance 300 (1H at 300MHz; 13C
at 75 MHz; 19F at 282 MHz spectra) and a BRUKER Advance II 400
(1H at 400 MHz and 13C at 101 MHz spectra). Chemical shifts are
given in parts per million (d) referenced to TMS (d = 0.00 ppm 1H and
13C NMR). The order of citation in parentheses is (1) multiplicity:
s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad
peak); (2) coupling constant (J) in Hz; and (3) number of equivalent
nuclei (by integration). HSQC and HMBC were routinely used to assign
peaks in 1H and 13CNMR spectra. High-resolutionmass spectra (HRMS)
measurements were performed by the Mass Spectrometry Service at
the Department of Chemistry and Biochemistry, University of Bern,
Switzerland on a Thermo Scientific LTQ OrbitrapXL. Absorption
spectra were measured with a Varian Cary 100 Bio UV-visible
spectrometer, and emission spectra were measured with a Varian
Cary Eclipse fluorescence spectrometer. Copies of 1H, 13C, and 19F
NMR spectra of synthetic intermediates and final compounds and
UV-Vis absorption and fluorescence emission spectra of fluorescent
probes are provided as Supplemental Data.
Compound Synthesis.
(2-Aminoethyl)cholic Amide. A solution of cholic acid (1 g,
2.45 mmol, 1 eq.) in methanol (25 ml) was treated with acetyl chloride
(25 ml, 25 mg, 0.32 mmol, 0.13 eq.) at room temperature. The reaction
was complete after 45 minutes. The solvent was concentrated in vacuo
to givemethyl cholate (1.1 g, quantitative) as a white foam (containing
small amounts of MeOH). 1H NMR (300 MHz, d6-DMSO) d 4.02 (br s,
containing HDO, MeOH, and the three OH), 3.77 (s, 1H), 3.61 (d, J =
3.0, 1H), 3.57 (s, 3H), 3.27–3.09 (m, 1H, partially overlapped with
theMeOH signal), 2.44–1.91 (m, 5H), 1.88–1.53 (m, 6H), 1.53–0.76 (m,
13H). 0.91 (d, J = 6.0, 3H), 0.80 (s, 3H), and 0.58 (s, 3H). HRMS m/z
calculated for C25H42N5Na [M+Na]
+ 445.2924, which found 445.2917,
D 21.70 ppm.
Methyl cholate (1.1 g, 2.62 mmol, 1 eq.) was added to ethylenedi-
amine (5 ml, 74.79 mmol, 29 eq.), and the resulting solution was
heated at reflux (140°C). After 3 hours the reaction was complete. The
reaction solution was then cooled to room temperature, and ice water
(50 ml) was added into the solution, after which a white precipitate
formed. The solid was filtered, washed with cold water, and dried
under reduced pressure to obtain (2-aminoethyl)cholic amide (Cen)
(848 mg, 72%). 1H NMR (300 MHz, d6-DMSO) d 7.69 (t, J = 5.6, 1H),
4.30 (s, 1H), 4.09 (s, 1H), 4.00 (d, J = 3.3, 1H), 3.78 (s, 1H), 3.61 (s, 1H),
3.18 (s, 1H), 3.00 (q, J = 6.2, 2H), 2.53 (q, J = 6.5, 2H), 2.32–0.74 (m,
26H), 0.92 (d, J = 6.2, 3H), 0.81 (s, 3H), and 0.58 (s, 3H). HRMS m/z
was calculated for C26H47N2O4 [M + H]
+ 451.3530, which found
451.3517, D 22.98 ppm. LC-MS tR 2.3 minutes, m/z [M + H]
+ 451.28.
(2-Aminoethyl)chenodeoxycholic Amide. Similarly to the syn-
thesis of Cen above, chenodeoxycholic acid (1 g, 2.54 mmol, 1 eq.) was
dissolved in MeOH (25 ml). Acetyl chloride (25 ml, 25 mg, 0.32 mmol,
0.13 eq.) was added at room temperature, and the resulting solution
was stirred overnight. The solvent was concentrated in vacuo to
give methyl chenodeoxycholate (1.1 g, quantitative) as a colorless
oil. 1H NMR (300 MHz, d6-DMSO) d 4.02 (br s, containing hydro-
deoxygenation, MeOH, and the two OH), 3.77 (s, 1H), 3.62 (d, J =
2.8, 1H), 3.57 (s, 3H), 3.27–3.08 (m, 1H, partially overlapped with
the MeOH signal), 2.42–2.08 (m, 3H), 1.97–1.53 (m, 7H), 1.53–0.78
(m, 16H), 0.88 (d, J = 6.4, 3H), 0.83 (s, 3H), 0.60 (s, 3H). HRMSm/z
was calculated for C25H42NaO4 [M + Na]
+ 429.2975, which found
429.2964, D 22.66 ppm.
Methyl chenodeoxycholate (1.1 g, 2.68 mmol, 1 eq.) was added to
ethylenediamine (5 ml, 74.79 mmol, 28 eq.). The resulting solution
was stirred overnight at room temperature and refluxed (140°C) for
2 hours. After that time, the reaction was complete. The reaction
solution was then cooled to room temperature, and ice water (7 ml)
was added into the solution at -10°C. Awhite precipitate formed. The
solid was filtered, washed with cold water, and dried under reduced
pressure. 1H NMR analysis of the solid showed presence of ethylenedi-
amine,whichwas responsible for the formation of anundesired byproduct
in the next step. The solid was repurified chromatographically (Combi-
Flash, SiO2, 100% EtOAc) to obtain (2-aminoethyl)chenodeoxycholic
amide (CDCen) (720 mg, 62%). 1H NMR (300 MHz, d6-DMSO) d 7.70
(t, J = 5.6, 1H), 4.31 (d, J = 4.6, 1H), 4.11 (d, J = 3.4, 1H), 3.62 (s, 1H),
3.17 (s, 1H), 3.00 (q, J = 6.2, 2H), 2.53 (q, J = 6.7, 2H), 2.34–1.54 (m, 10H),
1.53–0.85 (m, 18 H), 0.88 (d, J = 6.5, 3H), 0.83 (s, 3H), and 0.60 (s, 3H).
HRMS m/z was calculated for C26H47N2O3 [M + H]
+ 435.3581,
which found 435.3582, D 0.25 ppm. LC-MS tR 2.97 minutes, m/z
[M + H]+ 435.38.
CenNBD. 4-Chloro-7-nitrobenzofurazan (60mg, 0.3 mmol, 1.5 eq.)
was dissolved in anhydrous N,N-dimethylformamide (DMF) (2 ml).
After the addition of triethylamine (60 ml, 44 mg, 0.44 mmol, 2.2 eq.)
and Cen (90 mg, 0.2 mmol, 1 eq.), the mixture was stirred at room
temperature for 3 hours. The reaction solution was diluted with
water (30ml) and extractedwith ethyl acetate (5 15ml). The organic
layer was washed with water (5 10 ml) and then dried over Na2SO4.
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After evaporation under reduced pressure, a brown-green solid was
obtained. The crudewas purified byCombiFlash (SiO2, 4 g, EtOAc/MeOH
10:0 to 8:2, compounds eluted between 15% and 20%MeOH). The final
compound was isolated as a yellow/reddish solid (58 mg, 48%). 1H
NMR (300 MHz, d6-DMSO) d 9.40 (s, 1H), 8.53 (d, J = 8.9, 1H), 8.00 (t,
J = 5.8, 1H), 6.43 (d, J = 9.0, 1H), 4.30 (d, J = 4.2, 1H), 4.07 (d, J = 3.3,
1H), 3.99 (d, J = 3.4, 1H), 3.72 (d, J = 3.3, 1H), 3.56 (m, 3H), 3.39 (q, J =
5.7, 1H), 3.17 (m, 1H), 2.30–1.86 (m, 6H), 1.86–1.50 (m, 6H), 1.50–0.69
(m, 16H), 0.87 (d, J = 6.1, 3H), 0.79 (s, 3H), and 0.49 (s, 3H). 13C NMR
(75 MHz, d6-DMSO) d 173.40, 145.36, 144.39, 144.06, 137.85, 120.82,
99.11, 70.94, 70.40, 66.20, 48.56, 46.04, 45.65, 43.26, 41.49, 41.27,
39.44, 35.27, 34.95, 34.86, 34.34, 32.42, 31.46, 30.37, 28.50, 27.18,
26.31, 26.17, 22.70, 22.55, 17.06, and 12.22. HRMSm/zwas calculated
for C32H48N5O7 [M +H]
+ 614.3548, which found 614.3554,D 0.97 ppm.
LC-MS tR 3.57 minutes, 99% pure (at l214nm). UV-visible/Fluo (PBS
buffer + 1% DMSO): lmax abs 478 nm, lmax em 545 nm.
CDCenNBD. Analogously to CenNBD, the title compound was
prepared from 4-chloro-7-nitrobenzofurazan (60mg, 0.3 mmol, 1.5 eq.)
and CDCen (86 mg, 0.2 mmol, 1 eq.) in the presence of triethylamine
(60 ml, 44 mg, 0.44 mmol, 2.2 eq.) in DMF (2 ml). The crude was
purified twice by CombiFlash (SiO2, 4 g, EtOAc/MeOH 10:0 to 8:2)
to obtain the final compound as a yellow/reddish solid (50 mg, 42%).
1H NMR (300 MHz, d6-DMSO) d 9.40 (s, 1H), 8.53 (d, J = 8.9, 1H),
8.01 (t, J = 5.7, 1H), 6.43 (d, J = 9.0, 1H), 4.30 (d, J = 4.6, 1H), 4.09
(d, J = 3.4, 1H), 3.56 (m, 3H), 3.38 (q, J = 5.8, 2H), 3.25–3.10 (m, 1H),
2.33–1.52 (m, 12H), 1.52–0.72 (m, 24H), and 0.51 (s, 3H). 13C NMR
(101 MHz, d4-MeOD) d 177.71, 146.83, 145.80, 145.39, 138.47, 123.30,
99.95, 72.84, 69.03, 57.20, 51.42, 44.68, 43.59, 43.11, 40.90, 40.70,
40.41, 39.08, 36.71, 36.51, 36.16, 35.83, 34.07, 33.97, 33.12, 31.32,
29.17, 24.53, 23.36, 21.70, 18.89, and 12.12. HRMSm/zwas calculated
for C32H48N5O6 [M + H]
+ 598.3599, which found 598.3592, D21.24 ppm.
LC-MS tR 3.86 minutes, 95% pure (at l214nm).
AcenNBD. The same procedure was used as for CenNBD above.
4-Chloro-7-nitrobenzofurazan (293 mg, 1.47 mmol, 1.47 eq.) andN-(2-
aminoethyl) acetamide (95 ml, 102 mg, 1 mmol, 1 eq.) reacted in the
presence of triethylamine (300 ml, 218 mg, 2.15 mmol, 2.2 eq.) in DMF
(10ml). The crudewas purified by CombiFlash (SiO2, 12 g, EtOAc/MeOH
10:0 to 8:2). Only the purest fractions were collected, as many were
contaminated with traces of a fluorescent byproduct, and the final
compound was isolated as a yellow/reddish solid (22 mg, 8%). 1H NMR
(300MHz, d6-DMSO) d 9.44 (br s, 1H), 8.54 (d, J = 8.9, 1H), 8.07 (t, J =
5.9, 1H), 6.43 (d, J = 9.0, 1H), 3.53 (br s, 2H), 3.35 (q, J = 6.1, 2H), and
1.80 (s, 3H). 13C NMR (101 MHz, d6-DMSO) d 169.94, 145.37, 144.46,
144.10, 137.93, 120.86, 99.12, 43.10, 37.28, and 22.58. HRMSm/zwas
calculated for C10H11N5O4 [M + H]
+ 266.0884, which found 266.0884,
D 0.04 ppm. LC-MS tR 2.02 minutes, .90% pure (at l214nm).
CenDNS. Dansyl chloride (30 mg, 0.11 mmol, 1.1 eq.) was
dissolved in dichloromethane (DCM) (1 ml) and added to Cen (45
mg, 0.1 mmol, 1 eq.) in DCM (1 ml) at 0°C, which was followed by the
addition of triethylamine (30 ml, 22 mg, 0.22 mmol, 2.2 eq.). The
resulting solution was stirred overnight while slowly warming up to
room temperature. After 18 hours, the reaction solution was diluted
with aq. NaHCO3 (5 ml) and extracted with ethyl acetate (3  25 ml),
and the organic layer was dried over Na2SO4 and evaporated under
reduced pressure. The crude was purified by CombiFlash (SiO2, 12 g,
EtOAc/MeOH 10:0 to 8:2). The title compound was obtained as pale
yellow solid (51mg, 75%). 1HNMR (300MHz, d6-DMSO) d 8.46 (dt, J =
8.5, 1.1, 1H), 8.26 (d, J = 8.6, 1H), 8.08 (dd, J = 7.3, 1.2, 1H), 7.94 (t, J =
5.8, 1H), 7.69 (t, J = 5.7, 1H), 7.60 (m, 2H), 7.26 (dd, J = 7.7, 0.9, 1H),
4.31 (d, J = 4.3, 1H), 4.07 (d, J = 3.6, 1H), 3.99 (d, J = 3.4, 1H), 3.75 (d,
J= 3.4, 1H), 3.60 (br s, 1H), 3.25–3.10 (m, 1H), 3.02 (q, J= 6.3, 2H), 2.83
(s, 6H), 2.76 (q, J = 6.2, 2H), 2.37–0.76 (m, 24H), 0.87 (d, J = 6.2, 3H),
0.81 (s, 3H), and 0.53 (s, 3H). 13C NMR (101 MHz, d4-MeOD) d 177.16,
153.29, 136.74, 131.29 (2C), 130.92, 130.29, 129.21, 124.31, 120.45,
116.47, 74.04, 72.89, 69.05, 48.00, 47.48, 45.81 (2C N(CH3)2), 43.34,
43.22, 43.00, 41.03, 40.49, 40.28, 36.83, 36.50, 35.91, 33.98, 33.07,
31.20, 30.73, 29.60, 28.66, 27.89, 24.21, 23.17, 17.74, and 12.99. 13C
NMR (101 MHz, d6-DMSO) d 172.76, 151.35, 135.73, 129.42, 129.05,
128.98, 128.26, 127.83, 123.52, 118.97, 115.11, 70.95, 70.39, 66.20,
48.55, 46.03, 45.67, 45.03, 41.95, 41.49, 41.32, 38.46, 35.28, 35.01,
34.86, 34.35, 32.37, 31.47, 30.37, 28.52, 27.22, 26.18, 22.73, 22.59,
17.05, and 12.26 (one signal overlapped with the solvent signal).
HRMS m/z was calculated for C38H58N3O6S [M + H]
+ 684.4041,
which found 684.4043, D 0.32 ppm. LC-MS tR 3.48 minutes, 97% pure
(at l214nm). UV-visible/Fluo (MeOH + 1% DMSO): lmax abs 334 nm,
lmax em 520 nm.
CDCenDNS. The procedure above was used for the synthesis of
CDCenDNS, starting from dansyl chloride (60mg, 0.22mmol, 1.1 eq.)
andCDCen (86 mg, 0.2 mmol, 1 eq.) in DCM (2 ml) and triethylamine
(60 ml, 44 mg, 0.44 mmol, 2.2 eq.). After purification by CombiFlash
(SiO2, 4 g, EtOAc/MeOH 10:0 to 8:2), the final compound was isolated
as a pale yellow solid (81 mg, 61%). 1H NMR (300 MHz, d6-DMSO) d
8.46 (d, J = 8.5, 1H), 8.26 (d, J = 8.7, 1H), 8.08 (dd, J = 7.3, 1.3, 1H), 7.94
(t, J = 5.9, 1H), 7.69 (t, J = 5.7, 1H), 7.60 (m, 2H), 7.26 (d, J = 7.4, 1H),
4.31 (d, J = 4.7, 1H), 4.10 (d, J = 3.5, 1H), 3.62 (s, 1H), 3.02 (q, J = 6.5,
2H), 2.83 (s, 6H), 2.76 (q, J = 6.6, 2H), 2.19 (q, J = 12.9, 1H), 2.07–0.66
(m, 35H), and 0.54 (s, 3H). 13C NMR (75 MHz, d4-MeOD) d 177.07,
153.17, 136.67, 131.25, 131.17, 130.86, 130.25, 129.19, 124.29, 120.40,
116.37, 72.80, 68.96, 57.15, 51.46, 45.82, 43.60, 43.32, 43.10, 40.98,
40.70, 40.41, 40.37, 36.77, 36.53, 36.17, 35.87, 33.98, 33.94, 33.04,
31.34, 29.21, 24.58, 23.43, 21.75, 18.94, and 12.22. HRMS m/z was
calculated for C38H58N3O5S [M +H]
+ 668.4092, which found 668.4080,
D 21.72 ppm. LC-MS tR 3.80 minutes, 99% pure (at l214nm).
AcenDNS. This control compoundwasprepared similarly toCenDNS
and CDCenDNS from N-(2-aminoethyl) acetamide (95 ml, 102 mg,
1 mmol, 1 eq.) and dansyl chloride (290 mg, 1.077 mmol, 1.077 eq.) in
DCM (7.5 ml) and triethylamine (300 ml, 218 mg, 2.15 mmol, 2.2 eq.).
The crude was purified by CombiFlash (SiO2, 12 g, EtOAc/MeOH 10:0
to 8:2) to obtain AcenDNS as a pale yellow solid (275 mg, 82%). 1H
NMR (300MHz, d6-DMSO) d 8.47 (d, J = 8.5, 1H), 8.28 (d, J = 8.7, 1H),
8.10 (dd, J = 7.3, 1.2, 1H), 7.96 (br s, 1H), 7.77 (t, J = 5.6, 1H), 7.63 (dd,
J = 8.6, 7.3, 1H), 7.60 (dd, J = 8.5, 7.7, 1H), 7.27 (dd, J = 7.6, 0.9, 1H),
3.09–2.93 [m (pseudo q), 2H], 2.84 (s, 6H), 2.79 (t, J = 6.9, 2H), and 1.69
(s, 3H). 13C NMR (101 MHz, d6-DMSO) d 169.32, 151.37, 135.75,
129.45, 129.07, 129.00, 128.30, 127.86, 123.58, 119.03, 115.14, 45.06,
41.91, 38.62, and 22.45. HRMS m/z was calculated for C16H21N3O3S
[M + H]+ 336.1376, which found 336.1370, D 21.90 ppm. LC-MS tR
2.32 minutes, .90% pure (at l214nm).
CenPB. Amine Cen (13 mg, 0.029 mmol, 1 eq.) was dissolved
in DMF (0.8 ml). Diisopropylethylamine (100 ml, 76 mg, 0.59 mmol,
20 eq.) was added, which was followed by Pacific Blue succinimidyl
ester (10mg, 0.029mmol, 1 eq.). Themixturewas stirred for 3 hours at
room temperature, after which the reaction mixture was evaporated
under reduced pressure. The crude was purified by column chroma-
tography (SiO2, EtOAc/MeOH 8:2), and the obtained compound was
recrystallized from water/MeOH (4:1). The pale yellow solid was
filtered, washed with cold water, and dried in vacuo to yield CenPB
(11 mg, 55%). 1H NMR (300 MHz, d6-DMSO) d 11.95 (br s, 1H)
8.63 (m, 2H), 7.86 (t, J = 5.3, 1H), 7.51 (d, J = 10.9, 1H), 4.29 (br s, 1H),
4.06 (m, 2H), 3.97 (br s, 1H), 3.72 (d, J = 3.4, 1H), 3.56 (br s, 1H),
3.4–3.11 (m, 4H, partially overlapped with the solvent signal),
2.34–1.85 (m, 6H), 1.86–1.53 (m, 6H), 1.48–1.02 (m, 10H), 1.02–0.73
(m, 2H), 0.89 (d, J = 6.2, 3H), 0.77 (s, 3H), and 0.48 (s, 3H). 13C NMR
(101 MHz, d6-DMSO) d 173.34, 162.68, 160.82, 147.69, 110.30 (d, J =
22.5), 71.48, 70.93, 66.71, 49.07, 46.71, 46.18, 42.02, 41.75, 39.28,
38.77, 35.78, 35.43, 35.34, 34.84, 33.06, 32.09, 30.88, 28.96, 27.72,
26.65, 23.23, 23.01, 17.57, 12.72. 19F NMR (282 MHz, d6-DMSO) d
2135.66 (br s). HRMSm/zwas calculated for C36H49F2N2O8 [M + H]
+
675.3451, which found 675.3453, D 0.24 ppm. LC-MS tR 3.23 minutes,
97% pure (at l214nm). UV-visible/Fluo (PBS buffer + 1% DMSO):
lmax abs 410 nm, lmax em 451 nm.
CDCenPB. Analogously to above, CDCen (50 mg, 0.115 mmol, 1
eq.) was dissolved in DMF (2 ml). Diisopropylethylamine (200 ml, 152
mg, 1.176mmol, 10 eq.) was added, which was followed by Pacific Blue
succinimidyl ester (39mg, 0.115mmol, 1 eq.). Themixture was stirred
for 4 hours at room temperature, and the reaction mixture was
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evaporated under reduced pressure. The crude was purified by
CombiFlash (SiO2, 4 g, EtOAc/MeOH 10:0 to 8:2) to give CDCenPB
(38 mg, 50%). 1H NMR (300 MHz, d6-DMSO) d 8.69 (d, J = 1.6, 1H),
8.64 (t, J= 5.7, 1H), 7.87 (t, J= 5.4, 1H), 7.59 (d, J= 10.7, 1H), 4.29 (br s,
1H), 4.13–4.01 (m, 2H), 3.57 (br s, 1H), 3.44–3.10 (m, 4H, partially
overlapped with the solvent signal), 2.33–0.85 (m, 26H), 0.85 (d, J =
6.3, 3H), 0.80 (s, 3H), and 0.49 (s, 3H). 13CNMR (101MHz, d4-MeOD) d
177.17, 164.63, 162.00, 152.24 (d, J = 243.0), 149.23, 147.00, 142.68
(dd, J = 38.0, 7.9), 140.06 (d, J = 6.5), 114.30, 110.89 (d, J = 21.3),
109.17–108.68 (m), 72.86, 69.01, 57.40, 51.43, 43.61, 43.16, 40.96,
40.74, 40.45, 40.29, 39.88, 36.72, 36.53, 36.17, 35.87, 34.21, 33.96,
33.21, 31.33, 29.21, 24.57, 23.33, 21.71, 18.91, and 12.17. 19F NMR
(282 MHz, d6-DMSO) d -135.48 (br s). HRMS m/z was calculated for
C36H48F2N2NaO7 [M +Na]
+ 681.3322, which found 681.3309, D21.86
ppm. LC-MS tR 3.53 minutes, 98% pure (at l214nm).
AcenPB. As above, N-(2-aminoethyl) acetamide (20 ml, 21 mg,
0.209 mmol, 1.77 eq.) and Pacific Blue succinimidyl ester (40 mg,
0.118 mmol, 1 eq.) reacted in the presence of diisopropylethylamine
(100 ml, 76 mg, 0.59 mmol, 20 eq.) in DMF. The crude was purified
by CombiFlash (SiO2, 4 g, EtOAc/MeOH 10:0 to 8:2) to obtain
AcenPB as a pale yellow solid (25 mg, 68%). 1H NMR (300 MHz,
d6-DMSO) d 12.10 (s, 1H), 8.70 (d, J = 1.6, 1H), 8.66 (t, J = 5.8, 1H),
7.96 (t, J = 5.5, 1H), 7.61 (d, J = 11.1), 3.36 (q, J = 6.1, 2H), 3.19 (q,
J = 6.1, 2H), and 1.80 (s, 3H). 13C NMR (101 MHz, d6-DMSO) d
169.49, 161.97, 160.12, 150.40 (dd, J = 240.9, 5.5), 147.27 (t, J = 3.3),
146.29–145.41 (m), 141.28 (d, J = 8.4), 139.56 (dd, J = 242.1, 7.9),
112.06, 110.06 (dd, J = 21.1, 3.0), 106.66–105.90 (m), 38.86, 38.36,
and 22.60. 19F NMR (282 MHz, d6-DMSO) d 2135.47 (t, J = 11.3).
HRMSm/zwas calculated for C14H12F2N2O5 [M +H]
+ 327.0787, which
found 327.0789, D 0.72 ppm. LC-MS tR 1.94 minutes, .90% pure
(at l214nm).
Results
Synthesis of Fluorescent Bile Salt Probes. Previous
examples of fluorescent BS derivatives indicate that the
carboxylic acid side chain at C-24 of the bile acid skeleton is
tolerant toward substitution with fluorescent dyes and other
moieties (Holzinger et al., 1997; Yamaguchi et al., 2006; Rais
et al., 2010; Dong et al., 2015; Testa et al., 2017). In addition,
we have decided to introduce a short ethylene diamine linker
unit to mimic the amino acids glycine and taurine, which are
commonly conjugated at this position in human bile acids
(Fig. 1A). With regards to the choice of fluorescent dyes, we
reasoned that small organic fluorescent dyes would interfere
the least with the transport mechanisms, and therefore we
conjugated NBD, DNS, and PB to the C-24 position of cholic
and chenodeoxycholic acid (Fig. 1B). Furthermore, these three
dyes could potentially mimic certain features of the natural
transport substrates; NBD and DNS both have slightly acidic
NH groups, the sulfonamide group of DNS is similar to the
sulfonic acid end group of taurine, and, due to the two strongly
electron-withdrawing fluorine atoms, the phenol group of PB
is always deprotonated under physiologic conditions like the
end groups of human bile acids (Fig. 1A).
The synthesis of the fluorescent BS derivatives started from
cholic or chenodeoxycholic acid, which were transformed to
the corresponding methyl esters (Scheme 1A). Aminolysis in
refluxing ethylenediamine yielded the two amide building
blocks Cen and CDCen. It is important at this point to
quantitatively remove any remaining ethylenediamine.
The three fluorescent dyes were then coupled to the primary
amine terminus of Cen and CDCen using standard con-
ditions and commercial dye reagents NBD chloride, dansyl
chloride, and Pacific Blue N-hydroxysuccinimid ester. The
isolated final probes were subjected to a number of purifi-
cation steps, including washing, precipitation, and chro-
matographic methods, to ensure that all traces of uncoupled
fluorescent dyes were removed. This is crucial, as several
studies in the past have shown that fluorescent dyes alone can
also act as transport substrates (De Bruyn et al., 2011; Patik
et al., 2015, 2018). Consequently, our extensive purification
efforts delivered the final fluorescent BS probes in high
purity (.95% according to NMR and high-pressure liquid
chromatography) albeit at the expense of isolated yields
(42–75%). In a similar fashion, we have also generated
truncated control compounds AcenNBD, AcenDNS, and
AcenPB, which lack the bile acid moiety. All final com-
pounds showed strong fluorescence emission in the region of
450–550 nm (Scheme 1B).
Fig. 1. (A) Structures of common human bile
salts. (B) Structures of synthetic fluorescent bile
salt derivatives.
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Generation of CHO-ASBT Cells. To demonstrate the
successful transfection of CHO cells with functional ASBT, we
determined their capacity for sodium-dependent BS uptake.
Figure 2A shows sodium-dependent uptake into transfected
CHO cells, which is absent in wild-type CHO cells. Figure 2B
confirms expression of ASBT by Western blotting and expres-
sion at the plasma membrane of transfected CHO cells by
immunofluorescence, which is again absent in wild-type cells.
Hence, we successfully established an ASBT-expressing CHO
cell line. For a final characterization of this novel cell line, we
determined the concentration dependence of sodium-dependent
uptake of taurocholate under initial uptake conditions. Figure 3
shows that the Km value is about 34 mM, which is in line with
published values (Craddock et al., 1998).
Inhibition of Transporters by Fluorescent Bile Salt
Probes. To test the different fluorescent BS derivatives as
potential substrates of BS and organic anion transporters,
we chose a two-tier approach. First, the new BS derivatives
were tested as potential inhibitors of a radioactively labeled
standard substrate for the respective carrier. Derivatives
Fig. 1. Continued.
Scheme 1. (A) Chemical synthesis of fluorescent bile salt derivatives. Reagents: Ac-Cl, acetyl chloride; Et3N, triethylamine; DMF; DCM; PB-OSu, PB
N-hydroxysuccinimid ester; DIPEA,N,N-diisopropylethylamine. (B) Absorption and emission properties of fluorescent bile salt derivatives. Normalized
UV-visible absorption and fluorescence emission spectra, CenNBD: lmax abs 478 nm, lmax em 545 nm; CenDNS: lmax abs 334 nm, lmax em 520 nm;
CenPB: lmax abs 410 nm, lmax em 451 nm. TLC, spotted compounds run on thin-layer chromatography plates (silica gel; ethyl acetate/methanol 8:2) and
excited at 366 nm. Note the difference in polarity between CenDNS and CenPB.
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inhibiting transport were secondly tested as potential
substrates by performing a transport experiment. Table 1
lists the uptake of standard substrates for all transporters
investigated. Comparing transport under control and transporter-
mediated conditions shows for all transporters a transporter-
to-control ratio ofmore than 2.5, whichmakes the test systems
amenable for the inhibition studies. Figure 4 shows a typical
inhibition experiment with an uptake transporter. This figure
clearly demonstrates the concentration-dependent inhibi-
tion of OATP1B1-mediated estrone-3-sulfate by CenNBD.
It should also be noted, that CenNBD did not affect the
plasma membrane barrier function of the cells, as even at
100 mM no increase of estrone-3-sulfate uptake into WT cells
was found. Figure 5 gives an example of the efflux trans-
porter BSEP. Here, ATP-dependent uptake of taurocholate
was inhibited by CDCenNBD in a concentration-dependent
manner. Similarly, no impact on vesicle membrane barrier
function was found, as evidenced by an unchanged taurocho-
late transport in the absence of ATP. Because of the number
of compounds to be tested on a large number of transporters,
the experiments were not designed to obtain IC50 values for
inhibiting fluorescent BS derivatives. Table 2 shows the
summary of the inhibition experiments with uptake trans-
porters. The pattern of inhibition is somewhat unexpected,
as NTCP is strongly inhibited in a concentration-dependent
manner by all fluorescent BS derivatives with the exception
of CDCenDNS, which inhibits up to ∼55% at 100 mM. This
finding contrasts to some extent with the known restricted
substrate specificity of NCTP (Stieger, 2011). Among the
OATPs, the pattern is different and transporter-specific:
Strong inhibitionwas observed forCenNBD againstOATP1B3
and OATP2B1; CenDNS against OATP1B1 and OATP2B1;
CenPB against OATP1B3; andCDCenPB against OATP1B1,
OATP1B3, and OATP2B1. A weaker inhibition was found
forCenNBD against OATP1B1,CenDNS against OATP1B3,
CenPB against OATP1B1 and OATP2B1, CDCenNBD
against OATP1B3 and OATP2B1, and CDCenDNS against
OATP1B3 and OATP2B1. No relevant inhibition was ob-
served for CDCenNBD against OATP1B1 and CDCenDNS
against OATP1B1. Given the known broad substrate specific-
ity of OATPs (Obaidat et al., 2012; Hagenbuch and Stieger,
2013), a good inhibition of most OATPs was anticipated.
Finally, we also tested the intestinal BS transporter ASBT.
Unexpectedly, not one of the derivatives was a strong inhibitor:
With the exception of CDCenDNS and CDCenNBD (no
Scheme 1. Continued.
Fig. 2. Characterization of ASBT-expressing CHO cells. (A) Uptake of 5
mM taurocholate in WT and ASBT-expressing cells was measured for
3 minutes in the presence or absence of sodium as described in Materials
andMethods. (B) Left: Western blot of WT and ASBT-expressing cells. The
band for ASBT is indicated by an arrow. Right: immunolocalization of
ASBT at the plasma membrane of transfected cells (upper panel). Fig. 2. Continued.
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inhibition), all derivatives wereweak inhibitors. To exclude an
interference of the fluorophores with the transporter, trun-
cated probes AcenNBD, AcenDNS, and AcenPB were also
tested but showed no relevant interaction with transport of
test substrates (Table 2). The efflux transporter BSEP was
strongly inhibited by all BS derivatives, whereas the unconju-
gated fluorophores showed no interaction (Table 3). In contrast,
MRP2 tended to be stimulated rather than inhibited by theNBD
and DNS conjugates of the bile acids (Table 3). However, this
stimulation was also observed by the respective unconjugated
fluorophores AcenNBD and AcenDNS. In contrast, AcenPB
showed no interaction with MRP2, whereas CDCenPB stimu-
latedMRP2 transport activity at 10mMbut acted as an inhibitor
at 100 mM. The unconjugated AcenPB did not inhibit MRP2-
mediated transport of estradiol 17b-D-glucuronide.
Transport of Fluorescent Bile Salt Probes. Finally, we
assessed the fluorescent BS derivatives, which were positive
in the inhibition assay as potential transport substrates of
the investigated organic anion transporters. The data for the
uptake transporters are presented in Table 4. Overall, most
inhibitory interactions did not result in positive transport
data. None of the truncated fluorescent probes turned out to
be a substrate of any transporter investigated. As the CenPB
derivatives were neither a substrate for NTCP nor for ASBT,
AcenPB was not tested on these two transporters (Table 4).
ASBT does not transport any of the tested fluorescent BS
derivatives, and NTCP accepts CenDNS as substrate at low
capacity. CenNBD is a low-capacity substrate of OATP1B1
andOATP2B1.CenDNS is well transported byOATP1B3 and
Fig. 3. Kinetic analysis of taurocholate transport into ASBT-CHO cells.
Taurocholate uptake was determined as described in Materials and
Methods over 1 minute. Uptake was calculated as difference between
uptake in the presence of sodium and in the presence of choline. Data are
mean 6 S.D. of an experiment with triplicates.
TABLE 1
Uptake rates of tested transport systems
Transport experiments were performed as described in Material and Methods using the substrates and conc. given in the table. Uptake was normalized to picomole per
milligram protein  minute. The ratio was calculated by dividing transporter-mediated uptake rates by uptake rates under control conditions. Data are given as mean 6
S.D.
Transport System Substrate
Conditions
Ratio n
Choline Buffer Sodium Buffer
NTCP 5 mM taurocholate 39.6 6 20.9 135 6 77 3.6 6 1.7 12
ASBT 1 mM taurocholate 9.07 6 3.89 44.9 6 13.7 5.0 6 2.8 8
WT Transfected
OATP1B1 1 mM estrone-3-sulfate 6.62 6 2.06 78.8 6 30.5 12.7 6 0.9 15
OATP1B3 5 mM taurocholate 19.0 6 6.9 69.9 6 18.9 3.9 6 1.1 12
OATP2B1 1 mM estrone-3-sulfate 6.77 6 2.20 69.1 6 23.6 11.4 6 5.3 13
Without ATP With ATP
BSEP 2 mM taurocholate 6.97 6 1.77 39.9 6 10.8 6.2 6 2.8 11
MRP2 10 mM estradiol 17b-D-glucuronide 24.9 6 3.2 61.7 6 8.3 2.5 6 0.4 8
Fig. 4. Inhibition of 1 mM taurocholate uptake into WT (open bars) and
OATP1B1CHO cells (closed bars) in the presence of increasing concentrations
CenNBD. The difference between OATP1B1 CHO and WT cells (hatched
bars) is taken as OATP1B1-mediated transport. Transport was determined
for 40 seconds as described inMaterials andMethods. Data aremean6S.D. of
a representative experiment with three technical replicates.
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OATP2B1. Similar to CenNBD, CenPB is a low-capacity
substrate of OATP1B1, but it is also a substrate of OATP1B3.
CDCenNBD turned out to be a substrate for all hepatocellu-
lar OATPs, whereas CDCenDNS and CDCenPB are only
transported by OATP1B3 and OATP2B1. Table 5 demon-
strates that the ATP-binding cassette (ABC) transporters
BSEP and MRP2 do not transport the new fluorescent bile
acid derivatives. CenPB (BSEP) and CDCenPB (BSEP and
MRP2) were both positive in two independent experiments,
however, with large S.D. values. Hence, although these
compounds may be used as substrates for BSEP or MRP2,
transport experiments will be difficult given the high vari-
ability found here, and we would therefore rather conclude
that they are not transported.
Discussion
The aim of the present study was to thoroughly test the
impact of BS side-chain modifications with small fluorophores
on the interaction with hepatocellular organic anion trans-
porters, both with respect to inhibition and as potential
substrates. The main findings are that firstly, all tested uptake
transporters are inhibited by at least one novel bile acid
derivative (Table 2), whereby the interaction with ASBT was
more restricted than interaction with other transporters.
Secondly, neither NTCP (with the exception of a low transport
activity for CenDNS) nor ASBT transport fluorescent BS
derivatives, whereas all investigated OATPs accept more than
one derivative (Table 4). Thirdly, the efflux transporter BSEP is
subject to inhibition by all fluorescent bile acid derivatives,
whereas MRP2 is not inhibited but rather stimulated in some
instances (Table 3). Fourthly, efflux transport activity of the
new BS derivatives is, as compared with the uptake trans-
porters, very restricted (Table 5).
Given that, in particular, OATPs (Stieger and Hagenbuch,
2014) as well as MRP2 (van der Schoor et al., 2015) have a
very broad substrate specificity and both are able transporting
fluorescent dyes (Cantz et al., 2000; Brouwer et al., 2013;
Fig. 5. Inhibition of 2 mM taurocholate uptake in the absence (open
bars) and presence of ATP (closed bars) into BSEP-expressing insect
cell vesicles cells in the presence of increasing concentrations CDCenNBD.
The difference between uptake in the presence and absence of ATP (hatched
bars) is taken as BSEP-mediated transport. Transport was determined for
5 minutes as described inMaterials andMethods. Data are mean6 S.D. of
a representative experiment with three technical replicates.
TABLE 2
Inhibition of uptake transporters by fluorescent bile acid derivatives
Transport experiments were performed as described in Material and Methods. The
following substrates were used: NTCP, OATP1B3: 5 mM taurocholate; ASBT: 1 mM
taurocholate; and OATP1B1 and OATP2B1: 1 mM estrone-3-sulfate. Transport was
measured for 40 seconds. Substrate uptake values in % were corrected for uptake into
WT CHO cells. Uptake in the absence of inhibitor was set to 100%. Results are the
mean from two to four independent experiments with three technical replicates.
Compound [I] NTCP OATP1B1 OATP1B3 OATP2B1 ASBT
mM
CenNBD 0 100 100 100 100 100
0.1 98.5 101 108 90.9 95.8
1 108.3 95.1 83.0 76.6 86.5
10 38.7 64.9 26.6 23.0 76.4
100 4.9 9.4 22.9 3.6 64.2
CenDNS 0 100 100 100 100 100
0.1 85.9 98.8 82.7 94.0 85.5
1 49.1 89.2 57.0 55.5 80.1
10 7.8 30.4 13.0 11.5 59.4
100 2.4 16.5 41.7 7.4 47.9
CenPB 0 100 100 100 100 100
0.1 93.8 98.7 69.0 95.4 47.7
1 73.9 93.7 62.0 89.8 40.4
10 28.9 72.7 28.6 55.0 50.4
100 5.8 51.2 19.0 15.7 51.0
CDCenNBD 0 100 100 100 100 100
0.1 85.6 99.7 132 86.3 99.1
1 67.5 95.6 95.5 85.4 108
10 15.7 90.8 34.1 64.7 113
100 17.7 86.8 41.2 66.9 91.7
CDCenDNS 0 100 100 100 100 100
0.1 92.9 99.8 83.0 87.8 68.9
1 61.8 94.3 64.0 87.9 123
10 46.6 83.3 55.9 73.0 164
100 46.2 84.0 50.5 62.7 109
CDCenPB 0 100 100 100 100 100
0.1 64.5 91.9 56.7 98.0 43.4
1 29.6 71.5 37.5 60.5 42.3
10 6.7 36.3 28.8 13.2 48.6
100 3.9 3.1 19.8 3.7 45.3
AcenNBD 0 100 100 100 100 100
0.1 75.8 93.2 87.5 83.0 79.0
1 87.6 89.4 103 86.7 98.8
10 118 86.3 103 83.7 100
100 75.8 78.3 88.4 49.1 144
AcenDNS 0 100 100 100 100 100
0.1 92.7 99.6 109 95.8 82.0
1 110 94.8 102 95.7 92.2
10 120 93.5 94.8 114 99.6
100 80.2 90.8 69.9 147 101
AcenPB 0 ND 100 100 100 ND
0.1 ND 99.7 81.3 99.2 ND
1 ND 96.8 63.8 96.4 ND
10 ND 96.1 62.5 94.3 ND
100 ND 89.0 62.5 68.8 ND
ND, not determined.
354 Leuenberger et al.
 at A
SPE
T
 Journals on M
ay 21, 2021
jpet.aspetjournals.org
D
ow
nloaded from
 
Patik et al., 2015), special care was taken to separate the
desired reaction products (fluorescent bile acid conjugates)
with great purity from the fluorescent dye starting materials
after the synthetic coupling reactions. As an additional
control, possible interactions of the fluorescent dyes with
the investigated transporters were probed. To this end, bile
acid–truncated fluorescent probes AcenNBD, AcenDNS,
andAcenPBwere tested as potential inhibitors and substrates.
Not one of these fluorophores was found to be a substrate.
Using the molecules as inhibitors, AcenNB weakly inter-
acted with OATP2B1, whereas AcenPB and AcenDNS
weakly inhibited OATP1B3. This interaction is not surpris-
ing, as different fluorescent molecules have been shown to be
transported by OATPs (Patik et al., 2015, 2018). In contrast,
AcenDNS exhibited stimulation of OATP2B1 activity at high
concentration. A stimulation of OATP2B1 transport activity
by small molecules has been reported for prostaglandins
(Pizzagalli et al., 2003) or steroids (Grube et al., 2006), but
such stimulation is not restricted to OATP2B1 (Stieger and
Hagenbuch, 2014). All fluorescent bile acid derivatives inter-
acted with the tested transporters. As all of these uptake
transporters are bile salt and bile acid transporters, we
conclude that coupling of fluorophores to the side chain does
not prevent the final probes from interacting with the re-
spective bile acid binding sites on the transporters. Notably,
CDCenDNS tended to transiently stimulate the transport
activity of ASBT. This, to our knowledge, is a new finding, and
a similar observation was made for silibinin for the low-
affinity binding site of OATP1B1 (Wlcek et al., 2013). The
truncated fluorescent probes did not interact with BSEP, but
AcenNBD and AcenDNS were able to stimulate the trans-
port activity of MRP2. A stimulation of the transport activity
of MRP2 has also been reported for bosentan (Mano et al.,
2007) and other selected drugs (Lagas et al., 2009; Gilibili
et al., 2018).
In essence, neither NTCP nor ASBT transported any of the
tested substrates. However, it cannot be concluded from this
finding that modification of the side chain prevents bile salts
to be substrates of NTCP. Since endogenous conjugation of
taurine as well as glycine to the side chain of bile acids is via
amide bond, we also coupled the fluorescent dyes to the side
chain by an amide bond in the present work, similarly to an
earlier study (Maglova et al., 1995). These authors report
that two different side-chain derivatives of cholate were
taken up in part in a sodium-dependentmanner into primary
rat hepatocytes, whereas an identical side-chain derivative
of chenodeoxycholate displayed no dependence on sodium
(Maglova et al., 1995). A fluorescein side-chain derivative of
glycocholate was shown to be imported into rat hepatocytes
in a sodium-dependent manner, indicating transport by rat
NTCP (Grüne et al., 1996). On the other hand, a lysyl-fluorescein
side-chain derivative of cholate was not transported by NTCP
(de Waart et al., 2010). A fluorescent side-chain derivative
of cholate has previously been shown to be transported by
TABLE 3
Inhibition of efflux transporters by fluorescent bile acid derivatives
Transport experiments were performed as described in Material and Methods. The
following substrates were used: BSEP 2 mM taurocholate and MRP2 10 mM estradiol
17b-D-glucuronide. Transport was measured for 5 minutes. Substrate uptake values
in % were corrected for transport in the absence of ATP, and uptake in the absence of
inhibitor was set to 100%. Results are the mean from two to four independent
experiments with three technical replicates.
Compound [I] BSEP MRP2
mM
CenNBD 0 100 100
1 87.5 94.5
10 46.0 124
100 12.0 140
CenDNS 0 100 100
1 82.0 78.5
10 50.5 106
100 6.0 152
CenPB 0 100 100
1 80.0 94.5
10 58.0 94.5
100 16.5 91.0
CDCenNBD 0 100 100
1 67.5 122
10 40.5 151
100 6.5 228
CDCenDNS 0 100 100
1 85.5 115
10 43.0 132
100 25.5 179
CDCenPB 0 100 100
1 61.5 107
10 13.0 151
100 0.5 59.3
AcenNBD 0 100 100
1 103 136
10 97.5 132
100 94.5 145
AcenDNS 0 100 100
1 96.5 139
10 97.0 136
100 87.5 151
AcenPB 0 100 100
1 116 99
10 108 95
100 102 93
TABLE 4
Transport of fluorescent bile acid derivatives by uptake transporters
Transport experiments were performed as described in Material and Methods. The substrate conc. were 5 mM, and transport was measured for 5 minutes. Uptake values were
corrected for uptake into WT CHO cells. Results are given in picomole per milligram protein  5 minutes. Data are mean 6 S.D. from two to four independent experiments
with three technical replicates.
Compound NTCP OATP1B1 OATP1B3 OATP2B1 ASBT
CenNBD NT 67.0 6 30.0 NT 26.1 6 13.7 NT
CenDNS 20.3 6 10.0 NT 1577 6 509 175 6 20.2 NT
CenPB NT 21.6 6 13.1 306 6 188 NT NT
CDCenNBD NT 908 6 309 8545 6 3200 1779 6 405 NT
CDCenDNS NT NT 1524 6 311 141 6 26.61 NT
CDCenPB NT NT 162 6 59.7 60.5 6 18.4 NT
AcenNBD NT NT NT NT NT
AcenDNS NT NT NT NT NT
AcenPB ND NT NT NT ND
ND, not determined; NT, no transport.
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heterologously expressed NTCP and rNTCP (De Bruyn et al.,
2014). While developing fluorinated BS derivatives amenable
to positron emission tomography studies, it was observed that
a lithocholic acid derivative with a modified side chain was
accepted by NTCP as substrate (Testa et al., 2017). Hence,
based on the current literature, it is hard to predict the impact
of side-chain modification of bile acids affecting their sub-
strate properties for NTCP. It should be pointed out, however,
that the substrate pattern of NTCP not only includes bile salts
but also other organic anions as well as some drugs (Anwer
and Stieger, 2014). It is interesting to note that a substrate
pharmacophore for NTCP without consideration of the side
chain has been presented (Greupink et al., 2012; Dong et al.,
2015). There is a consensus that the substrate specificity of
ASBT is much narrower than that of NTCP (Claro da Silva
et al., 2013; Anwer and Stieger, 2014; Dawson and Karpen,
2015). In this context, the results for ASBTwere not surprising.
Given the broad substrate specificity of OATPs, we expected
that they would also transport some of our novel BS deriva-
tives (Table 4). Here, it is interesting to note that OATP2B1
transports five out of the six tested fluorescent BS probes. This
is in contrast with an earlier study, in which we found no
transport of conjugated bile acids byOATP2B1 (Kullak-Ublick
et al., 2001). It is, however, very reassuring that none of the
fluorescent dyes we used was a substrate of the tested OATPs.
Hence, these dyesmight be coupled to different positions of the
bile acid skeleton (Yamaguchi et al., 2006).
Given that a fluorescent side-chain derivative of bile salts
was reported to be a BSEP substrate (Yamaguchi et al., 2010),
it was somewhat unexpected that none of our derivatives
was transported by BSEP. However, our data fit well with
the concept that BSEP transports almost exclusively conju-
gated bile acids (Stieger, 2011). Although all derivatives were
inhibitors of BSEP, none of the truncated fluorescent probes
significantly interactedwith this transporter. AlthoughMRP2
transports a wide variety of endogenousmetabolites as well as
drug and xenobiotic metabolites (Keppler, 2011), none of our
bile acid derivatives was a good substrate. This is interesting
in view of the fact that some of our derivatives were able
to stimulate transport activity of a prototypical substrate of
MRP2. This may, at least in part, be explained by the rather
complex transport kinetics of MRP2 (Guyot et al., 2014).
Again, none of the fluorescent dyes used here was transported
by MRP2. However, it should be kept in mind that extrapo-
lation of driving forces from in vitro systems to in vivo
situations is very difficult at best. It can therefore not be
excluded that in an in vivo model CDCenPB might be taken
up into a liver system and secreted into bile. As it is possible to
keep livers with continuous perfusion alive out of bodies for
up to a week now (Eshmuminov et al., 2020, 2021),CDCenPB
for instance could be evaluated as a dynamic liver function
marker in ex situ perfused (human) livers.
In conclusion, side-chain modification of bile acids does not
prevent the conjugates interacting with organic anion and
bile salt uptake and efflux transporters. However, the new
fluorescent compounds are not transport substrates for bile
acid uptake transporters NCTP andASBT. Furthermore, with
the exception of CDCenPB, they are not transported by the
canalicular efflux transporters and thus are not suitable
for in vivo studies. Nevertheless, these new fluorescent BS
derivatives have some potential as imaging agents if sub-
strate uptake into hepatocytes or cells is to be followed. Since
CDCenPBmay be both a substrate of the uptake transporters
OATP1B3 and OATP2B1 as well as of the canalicular efflux
transportersBSEPandMRP2, future studies in in vivomodels of
bile formation with this compound are warranted.
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